• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

Busy schedule planned for AGM 2024 in Zagreb

Lung Cancer Europe (LuCE) Annual General Meeting and General Assembly The Lung Cancer Europe (LuCE) AGM and General Assembly take […]

BMS Press Release is out now

Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]

Press Release: High risk of financial vulnerability after diagnosis: The majority of people impacted by lung cancer experience higher costs and reduction in income

Financial impact of lung cancer: A European perspective High risk of financial vulnerability after diagnosis:  The majority of people impacted […]

8th Edition of the LuCE Report – Financial impact of lung cancer: A European perspective

This is an annual initiative led by lung cancer patient organisations, across Europe with the purpose of raising awareness relating […]

8th LuCE Report on Lung Cancer: Launch Event

Join us at our launch of the 8th LuCE report: “Financial impact on lung cancer: A European Perspective”

LuCE attending the European Medicines Agency (EMA) in Amsterdam

November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting […]


Privacy policy
Terms & Conditions

© 2025 Lung Cancer Europe – All Rights Reserved